POINT BIOPHARMA GLOBAL INC. Research and Development Expense
POINT BIOPHARMA GLOBAL INC. reported Research and Development Expense of $26.91 million for the 3-month period ending 2023-09-30, per its 10-Q filed 2023-11-13.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2023-11-13
- POINT BIOPHARMA GLOBAL INC. research and development expense for the quarter ending 2023-09-30 was $26.91M, a 29.39% increase year-over-year.
- POINT BIOPHARMA GLOBAL INC. research and development expense for the quarter ending 2023-06-30 was $31.28M, a 50.27% increase year-over-year.
- POINT BIOPHARMA GLOBAL INC. research and development expense for the quarter ending 2023-03-31 was $26.91M, a 115.27% increase year-over-year.
- POINT BIOPHARMA GLOBAL INC. research and development expense for the quarter ending 2022-12-31 was $27.94M, a 193.14% increase year-over-year.
- POINT BIOPHARMA GLOBAL INC. research and development expense for fiscal 2022 was $82.05M, a 144.89% increase from fiscal 2021.
- POINT BIOPHARMA GLOBAL INC. research and development expense for fiscal 2021 was $33.51M, a 266.49% increase from fiscal 2020.
- POINT BIOPHARMA GLOBAL INC. research and development expense for fiscal 2020 was $9.14M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2023-09-30 | $26.91M 10-Q · filed 2023-11-13 | $58.19M derived: sum of 2 quarters · filed 2023-11-13 | $85.10M 10-Q · filed 2023-11-13 | $113.04M derived: sum of 4 quarters · filed 2023-11-13 |
| 2023-06-30 | $31.28M 10-Q · filed 2023-08-14 | $58.19M 10-Q · filed 2023-08-14 | $86.13M derived: sum of 3 quarters · filed 2023-08-14 | $106.92M derived: sum of 4 quarters · filed 2023-11-13 |
| 2023-03-31 | $26.91M 10-Q · filed 2023-05-15 | $54.85M derived: sum of 2 quarters · filed 2023-05-15 | $75.65M derived: sum of 3 quarters · filed 2023-11-13 | $96.46M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-12-31 | $27.94M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27 | $48.74M derived: sum of 2 quarters · filed 2023-11-13 | $69.55M derived: sum of 3 quarters · filed 2023-11-13 | $82.05M 10-K · filed 2023-03-27 |
| 2022-09-30 | $20.80M 10-Q · filed 2023-11-13 | $41.61M derived: sum of 2 quarters · filed 2023-11-13 | $54.11M 10-Q · filed 2023-11-13 | $63.64M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $20.81M 10-Q · filed 2023-08-14 | $33.31M 10-Q · filed 2023-08-14 | $42.85M derived: sum of 3 quarters · filed 2023-08-14 | $55.85M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $12.50M 10-Q · filed 2023-05-15 | $22.03M derived: sum of 2 quarters · filed 2023-05-15 | $35.04M derived: sum of 3 quarters · filed 2023-05-15 | $41.74M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $9.53M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27 | $22.54M derived: sum of 2 quarters · filed 2023-03-27 | $29.24M derived: sum of 3 quarters · filed 2023-03-27 | $33.51M 10-K · filed 2023-03-27 |
| 2021-09-30 | $13.00M 10-Q · filed 2022-11-14 | $19.71M derived: sum of 2 quarters · filed 2022-11-14 | $23.97M 10-Q · filed 2022-11-14 | $28.09M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $6.70M 10-Q · filed 2022-08-12 | $10.97M 10-Q · filed 2022-08-12 | $15.09M derived: sum of 3 quarters · filed 2022-08-12 | $17.57M derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | $4.27M 10-Q · filed 2022-05-13 | $8.39M derived: sum of 2 quarters · filed 2022-05-13 | $10.87M derived: sum of 3 quarters · filed 2022-05-13 | $13.03M derived: sum of 4 quarters · filed 2022-05-13 |
| 2020-12-31 | $4.12M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-25 | $6.60M derived: sum of 2 quarters · filed 2022-03-25 | $8.76M derived: sum of 3 quarters · filed 2022-03-25 | $9.14M 10-K · filed 2022-03-25 |
| 2020-09-30 | $2.48M 10-Q · filed 2021-11-12 | $4.64M derived: sum of 2 quarters · filed 2021-11-12 | $5.02M 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $2.16M 10-Q · filed 2021-08-13 | $2.54M 10-Q · filed 2021-08-13 |